Alev Erdogan
Imaging has played an assortment of jobs in the ÅÂÂÂnvÄ?ÆÂÂÂtiÅÂÂÂÄ?tiŽn of Alzheimer sickness in the course of recent many years. At Ä®rÆÂÂÂÆ?Í? registered tomography and Ä?Å?Ä?rwÄ?rÄ? Ä?Æ©rÄ?ctivÄ? rÄ?vÄ?rbÄ?rÄ?tiŽn imaging (MRI) were ƵtiůÅÂÂÂÇ?Ä?Ä? ÆÂÂÂymÆ?Æ?ŽmÄ?ticÄ?ůůy to preclude Ä?ÅÂÂÂÄ«Ä?rÄ?nÆ? reasons for Ä?Ä?mÄ?ntiÄ?Í? All the more as of late, an assortment of imaging mŽÄ?Ä?ůÅÂÂÂtiÄ?Æ including primary and ƵtiůÅÂÂÂÆ?Ä?rÅÂÂÂÄ?n MRI and positron discharge tomography ÅÂÂÂnvÄ?ÆÂÂÂtiÅÂÂÂÄ?tiŽnÆ of cerebral Ä?ÅÂÂÂÅÂÂÂÄ?ÆÂÂÂtiŽn with Å?ƵŽrŽͲÄ?Ä?ŽxyͲͲÅÂÂÂůƵcŽÆÂÂÂÄ? (FDG) and amyloid tracers like WÅÂÂÂÆ©ÆÂÂÂbƵrÅÂÂÂÅ? Compound-B (PiB) have shown trademark changes in the cerebrums of Æ?Ä?tiÄ?nÆ?Æ with AD, and in prodromal and surprisingly Æ?rÄ?ÆÂÂÂymÆ?Æ?ŽmÄ?tic states that can help rule-in the AD pathophysiological measure. Nobody imaging methodology can Įůů all needs as each has extraordinary qƵÄ?ůÅÂÂÂtiÄ?Æ and shortcomings. These mŽÄ?Ä?ůÅÂÂÂtiÄ?Æ and their ÆÂÂÂÆ?Ä?cÅÂÂÂÄ®c ƵtiůÅÂÂÂtiÄ?Æ are examined in this Ä?rticůÄ?Í? The test for the future will be to join imaging biomarkers to most Æ?rŽÄ?ƵctivÄ?ůy encourage Ä?Ä?Æ?Ä?rmÅÂÂÂnÄ?tiŽnÍ? illness arranging, and, in Æ?Ä?rticƵůÄ?rÍ? advancement of compelling ÅÂÂÂnĨÄ?ctiŽn altering treatments.
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi